Genmab
(NASDAQ:GMAB)
$29.91
-0.72[-2.35%]
At close: Mar 28
$29.91
0[0.00%]
After Hours: 4:00PM EDT
Consensus Rating1
Market Perform
Highest Price Target1
$50.00
Lowest Price Target1
$32.00
Consensus Price Target1
$28.46

Genmab Stock (NASDAQ:GMAB), Analyst Ratings, Price Targets, Predictions

Genmab A/S has a consensus price target of $28.46, established from looking at the 64 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Morgan Stanley, and Truist Securities on March 27, 2024, March 26, 2024, and March 26, 2024. With an average price target of $44 between HC Wainwright & Co., Morgan Stanley, and Truist Securities, there's an implied 47.11% upside for Genmab A/S from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
2
Nov 23
3
1
Jan
1
Feb
3
Mar
3
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Morgan Stanley
Truist Securities
BMO Capital
BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Genmab

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/27/2024GMABBuy Now
Genmab
$29.9167.17%HC Wainwright & Co.
Raghuram Selvaraju
$50 → $50MaintainsBuyGet Alert
03/26/2024GMABBuy Now
Genmab
$29.916.99%Morgan Stanley
Matthew Harrison
$32 → $32MaintainsUnderweightGet Alert
03/26/2024GMABBuy Now
Genmab
$29.9167.17%Truist Securities
Asthika Goonewardene
$50 → $50MaintainsBuyGet Alert
03/06/2024GMABBuy Now
Genmab
$29.9167.17%HC Wainwright & Co.
Raghuram Selvaraju
→ $50ReiteratesBuy → BuyGet Alert
02/23/2024GMABBuy Now
Genmab
$29.9160.48%BMO Capital
Etzer Darout
$46 → $48UpgradeMarket Perform → OutperformGet Alert
02/20/2024GMABBuy Now
Genmab
$29.9167.17%Truist Securities
Asthika Goonewardene
$54 → $50ReiteratesBuy → BuyGet Alert
02/20/2024GMABBuy Now
Genmab
$29.9167.17%HC Wainwright & Co.
Raghuram Selvaraju
→ $50ReiteratesBuy → BuyGet Alert
01/29/2024GMABBuy Now
Genmab
$29.9167.17%HC Wainwright & Co.
Raghuram Selvaraju
$49 → $50MaintainsBuyGet Alert
11/28/2023GMABBuy Now
Genmab
$29.9163.82%HC Wainwright & Co.
Raghuram Selvaraju
→ $49ReiteratesBuy → BuyGet Alert
11/20/2023GMABBuy Now
Genmab
$29.9163.82%HC Wainwright & Co.
Raghuram Selvaraju
→ $49ReiteratesBuy → BuyGet Alert
11/09/2023GMABBuy Now
Genmab
$29.916.99%Morgan Stanley
Matthew Harrison
$33 → $32MaintainsUnderweightGet Alert
11/08/2023GMABBuy Now
Genmab
$29.9163.82%HC Wainwright & Co.
Raghuram Selvaraju
$51 → $49MaintainsBuyGet Alert
10/18/2023GMABBuy Now
Genmab
$29.9170.51%HC Wainwright & Co.
Raghuram Selvaraju
→ $51ReiteratesBuy → BuyGet Alert
10/13/2023GMABBuy Now
Genmab
$29.9153.79%BTIG
Kaveri Pohlman
$44 → $46MaintainsBuyGet Alert
09/26/2023GMABBuy Now
Genmab
$29.9180.54%Truist Securities
Asthika Goonewardene
→ $54ReiteratesBuy → BuyGet Alert
09/06/2023GMABBuy Now
Genmab
$29.9180.54%Truist Securities
Asthika Goonewardene
→ $54ReiteratesBuy → BuyGet Alert
09/05/2023GMABBuy Now
Genmab
$29.9170.51%HC Wainwright & Co.
Raghuram Selvaraju
→ $51ReiteratesBuy → BuyGet Alert
08/24/2023GMABBuy Now
Genmab
$29.9147.11%BTIG
Kaveri Pohlman
→ $44Initiates → BuyGet Alert
08/15/2023GMABBuy Now
Genmab
$29.9170.51%HC Wainwright & Co.
Raghuram Selvaraju
→ $51ReiteratesBuy → BuyGet Alert

FAQ

Q

What is the target price for Genmab (GMAB)?

A

The latest price target for Genmab (NASDAQ: GMAB) was reported by HC Wainwright & Co. on March 27, 2024. The analyst firm set a price target for $50.00 expecting GMAB to rise to within 12 months (a possible 67.17% upside). 37 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Genmab (GMAB)?

A

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by HC Wainwright & Co., and Genmab maintained their buy rating.

Q

When was the last upgrade for Genmab (GMAB)?

A

The last upgrade for Genmab A/S happened on February 23, 2024 when BMO Capital raised their price target to $48. BMO Capital previously had a market perform for Genmab A/S.

Q

When was the last downgrade for Genmab (GMAB)?

A

The last downgrade for Genmab A/S happened on January 3, 2022 when Guggenheim changed their price target from N/A to N/A for Genmab A/S.

Q

When is the next analyst rating going to be posted or updated for Genmab (GMAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.

Q

Is the Analyst Rating Genmab (GMAB) correct?

A

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a maintained with a price target of $50.00 to $50.00. The current price Genmab (GMAB) is trading at is $29.91, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch